Brigacent 90mg Tablet is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic Non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to Crizotinib.
🛒 How to order this item?
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Show More
Brigatinib (Therapeutic Class: Cytotoxic Chemotherapy)
Non-Small Cell Lung Cancer
Brigatinib is a tyrosine kinase inhibitor with in vitro activity against multiple kinases, including ALK, ROS1, IGF-1R, FLT-3, and EGFR deletion/point mutations. It inhibits the autophosphorylation of ALK and downstream signaling proteins. Brigatinib has shown antitumor activity in various assays and animal models.
The recommended dosing regimen for Brigatinib is:
Brigacent 90mg Tablet is contraindicated in patients with known hypersensitivity to Brigatinib or any other components of this product.
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.
Disclaimer:
ePharma sole intention is to ensure that its consumers get proper
information as musch as possible. Although we do not guarantee the
accuracy and the completeness of the information that provided and
here information is for informational purposes only.
The information contained herein should NOT be used as a substitute
for the advice of a qualified physician. This may not cover
everything about particular health conditions,
lab tests, medicines, all possible side effects, drug interactions,
warnings, alerts, etc. Please consult your healthcare professional
and discuss all your queries related to any disease or medicine. We
intend to support, not replace, the doctor-patient relationship.